Pathways for aberrant angiogenesis in pancreatic cancer

被引：129

作者：

M Korc

机构：

[1] Div. of Endocrinol. Diabetes/Metab., Department of Medicine, University of California, Irvine

来源：

关键词：

Vascular Endothelial Growth Factor; Pancreatic Cancer; Hepatocyte Growth Factor; Pancreatic Cancer Cell; Pancreatic Cancer Cell Line;

D O I：

10.1186/1476-4598-2-8

中图分类号：

学科分类号：

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Although the specific mechanisms that dictate its biological aggressiveness are not clearly established, it is characterized by a variety of molecular alterations as well as by the overexpression of mitogenic and angiogenic growth factors and their receptors. PDACs also express high levels of vascular endothelial growth factor (VEGF). Recent studies indicate that suppression of VEGF expression attenuates pancreatic cancer cell tumorigenicity in a nude mouse model, and that VEGF can exert direct mitogenic effects on some pancreatic cancer cells. These findings suggest that cancer cell derived VEGF promotes pancreatic cancer growth in vivo via a paracrine angiogenic pathway and an autocrine mitogenic pathway, and provide novel opportunities for therapeutic intervention in this deadly disease. © 2003 Korc; licensee BioMed Central Ltd.

引用

页数：8

共 145 条

[121]

Lambert V., Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization, Faseb J., 15, 6, pp. 1021-1027, (2001)

[122]

Andreasen P.A., Egelund R., Petersen H.H., The plasminogen activation system in tumor growth, invasion, and metastasis, Cell Mol. Life Sci., 57, 1, pp. 25-40, (2000)

[123]

Munger J.S., Latent transforming growth factor-beta: Structural features and mechanisms of activation, Kidney Int., 51, 5, pp. 1376-1382, (1997)

[124]

Kojima S., Nara K., Rifkin D.B., Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells, J. Cell Biol., 121, 2, pp. 439-448, (1993)

[125]

Cantero D., Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma, Br. J. Cancer, 75, 3, pp. 388-395, (1997)

[126]

Ishiwata T., Altered expression of insulin-like growth factor II receptor in human pancreatic cancer, Pancreas, 15, 4, pp. 367-373, (1997)

[127]

Elsasser H.P., Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells, Eur. J. Cell Biol., 61, 2, pp. 321-328, (1993)

[128]

Haroon Z.A., Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis, Faseb J., 13, 13, pp. 1787-1795, (1999)

[129]

Mishima K., A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin, Proc. Natl. Acad. Sci. U. S. A., 97, 15, pp. 8484-8489, (2000)

[130]

Schwarte-Waldhoff I., Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis, Proc. Natl. Acad. Sci. U. S. A., 97, 17, pp. 9624-9629, (2000)

← 6 7 8 9 10 11 12 13 14 15 →